The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
October 25th 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
When Men Exercise Could Influence Risk of Cardiovascular Disease, Study Finds
February 23rd 2021An analysis of more than 2k patients from within the Look AHEAD study suggests the timing of physical activity could play a role in mitigating cardiovascular risk among men with type 2 diabetes considered overweight or obese.
Cardiovascular Health During Pregnancy Helps Predict Heart Health in Children, Study Finds
February 18th 2021An analysis of more than 2k mother-child pairs indicates assessments of maternal cardiovascular health could shed light on the potential for poor cardiovascular health among their children at ages 10-14 years.
More than 50% of Severe COVID-19 Patients Develop Subsequent Heart Damage
February 18th 2021An analysis of nearly 150 patients with severe COVID-19 and increased troponin levels indicates more than half of those patients went on to develop infarction, myocarditis, ischemia, or a combination of the three.
Sedentary Individuals at Increased Risk of Fatal Myocardial Infarction
February 15th 2021An analysis of more than 28k incident myocardial infarction events demonstrates increased physical activity levels were associated with a 21-45% lower risk of instant death and a 15-36% lower risk of death in the first 28 days.
Evinacumab (Evkeeza) Receives FDA Approval as Adjunct Therapy for HoFH
February 11th 2021A statement from Regeneron announced their ANGPTL3 inhibitor evinacumab (Evkeeza) received approval as an adjunct therapy for lowering LDL-C in patients 12 years and older with homozygous familial hypercholesterolemia.
Chinese Adults More Susceptible to Obesity-Related Health Complications than Other Ethnic Groups
February 11th 2021An analysis of data from an ethnically diverse cohort of more than 120k patients indicates Chinese adults were more susceptible to obesity-related health complications, such as hypertension, than other racial/ethnic groups.
Large-Scale Genetic Analysis Indicates Increased Blood Pressure Causes Atrial Fibrillation
February 11th 2021An analysis of data from the International Consortium of Blood Pressure-Genome Wide Association Studies suggests every 1 mmHg increase in blood pressure was linked to a 1.4-2.6% increase in risk of atrial fibrillation.
Medicare Patients Less Likely to be Prescribed GLP-1RAs, SGLT2 Inhibitors than Commercially Insured
February 10th 2021Data from an analysis of nearly 400k older patients suggests Medicare Advantage beneficiaries were less likely than their counterparts with commercial insurance to be prescribed newer glucose-lowering agents such as GLP-1RAs and SGLT2 inhibitors.